Tiziana Life Sciences reports positive phase 2a results for Intranasal Foralumab in MS

Tiziana Life Sciences (TLS) fell 13% on Monday despite phase 2a results for intranasal foralumab meeting dual primary endpoints in non-active secondary progressive multiple sclerosis. The 50 μg dose showed significant neuroinflammation reduction vs. placebo, while the 100 μg dose did not. Both doses were well-tolerated, and MFIS scores improved in treatment arms.

Tiziana Life Sciences (TLSA) reported positive Phase 2a trial results for intranasal foralumab in treating non-active secondary progressive MS, meeting primary endpoints. The 50 µg dose showed significant reduction in brain inflammation and fatigue. The stock is down 13.44% to $0.69.

Tiziana Life Sciences (TLSA) reported positive Phase 2a trial results for foralumab in non-active secondary progressive multiple sclerosis. The drug met primary endpoints, reducing brain inflammation and improving fatigue. No serious side effects were reported. TLSA plans to discuss findings with the FDA. The stock is currently trading at $0.67, down 15.08%.

Tiziana Life Sciences reported positive results from a mid-stage trial of its experimental MS treatment, foralumab. The therapy met primary endpoints, reducing brain inflammation and showing a favorable safety profile. Shares rose over 7% in premarket trading. The trial involved 48 patients across eight US sites, with no serious side effects reported.

Tiziana Life Sciences (TLSA) reported that its nasal MS drug foralumab reduced brain inflammation and was safe in a mid-stage trial for non-active secondary progressive multiple sclerosis. The 50-microgram dose showed a statistically significant reduction in neuroinflammation versus placebo, while both doses improved fatigue scores. The trial was not powered to show definitive clinical changes. The company plans to present detailed results and meet with the FDA.

Tiziana Life Sciences (TLSA) completed dosing in its Phase 2 trial of intranasal foralumab for early or mild Alzheimer's, with topline data expected in Q1 2027. The trial, assessing safety, tolerability, and efficacy, includes foralumab alone and in combination with lecanemab or donanemab. Key endpoints include changes in neuroinflammation, cognitive function, and fluid biomarkers.